Ubiquitous access to smartphones presents both a market opportunity and a conduit for clinical trials to more closely engage with patients.
As patient engagement grows as a focus of new drug development, particularly in the areas of clinical trial recruitment and participation, smartphones are expected to contribute more routinely as the primary interface between trial sponsors, PIs, and patients. Advances in life science-based technologies are shrinking traditional diagnostics platforms to sizes that will eventually be accessible by patients and consumers alike and will include intelligent systems that help to deliver the necessary robustness and performance validation needed to deliver accurate and useful information to users.
New app development, translation of traditional patient-centric diagnostic platforms (e.g. blood glucose meters) into smartphone friendly solutions, and tech innovation translating advanced smartphone features (e.g. cameras, voice recognition, motion sensors) into medical insights (e.g. fall detectors, mental acuity measurement) are coming very soon to a phone near you. Better trials and more medically informed consumers are on the horizon. It remains to be seen whether healthcare solutions will precede most clinical trial solutions, based on either market demand or clinical trial need.
As always, comments and alternative opinions are welcome.